
Foghorn Therapeutics fell 62.8% from $4.81 to $1.79, behind the S&P 500's +11.2%. Its worst day was Oct 2 (−30.8%), and its low came Nov 16 at $1.79.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026Phase 1 dose-escalation
+23.6%, the year's best day · S&P 500 +0.2%
Story events cover the past 12 months · Times ET
EPS of $-0.34 missed the $-0.27 estimate on $9.2M revenue (est. $8.9M).
−12.9% · S&P 500 −1.5%
EPS of $-0.29 beat the $-0.31 estimate on $3.3M revenue (est. $8.2M).
−10.3% · S&P 500 −0.3%
Foghorn Therapeutics shares rose 15.2%, while the S&P 500 rose 1.6%.
+15.2% · S&P 500 +1.6%
Foghorn Therapeutics shares rose 18.8%, while the S&P 500 fell 0.5%.
+18.8% · S&P 500 −0.5%
EPS of $-0.10 beat the $-0.23 estimate on $16.1M revenue (est. $8.0M).
+14.1% · S&P 500 −0.2%
Foghorn Therapeutics closed at its highest level of the year, 47.0% above where the year started.
+0.9% · S&P 500 +0.4%
Foghorn Therapeutics shares fell 30.8%, while the S&P 500 rose 0.7%.
−30.8%, the year's worst day · S&P 500 +0.7%
EPS of $0.80 beat the $-0.25 estimate on $83.5M revenue (est. $7.2M).
+9.1% · S&P 500 +2.4%
Where it ended: a close of $1.79 on Nov 16, 2026. Up next: Q4 2026 earnings on Mar 10, 2027 (EPS est. $-0.24, revenue est. $4.2M).
Nothing in the past 12 months.
All FHTX dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for FHTX and SPY from Benzinga historical bars. Not investment advice.